Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea

Dec 06, 2023

Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance

Dec 05, 2023

Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting

Dec 01, 2023

Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 14, 2023

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 14, 2023

Fortress Biotech Announces Closing of $10.0 Million Public Offering

Nov 14, 2023

Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 13, 2023

Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 13, 2023

Fortress Biotech Announces Pricing of $10.0 Million Public Offering

Nov 10, 2023

Fortress Biotech Announces Launch of Proposed Public Offering

Nov 09, 2023